<SEC-DOCUMENT>0001209191-18-054253.txt : 20181004
<SEC-HEADER>0001209191-18-054253.hdr.sgml : 20181004
<ACCEPTANCE-DATETIME>20181004162827
ACCESSION NUMBER:		0001209191-18-054253
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20181004
FILED AS OF DATE:		20181004
DATE AS OF CHANGE:		20181004

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			MCKENZIE W  THORPE
		CENTRAL INDEX KEY:			0001211462

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37347
		FILM NUMBER:		181108156

	MAIL ADDRESS:	
		STREET 1:		735 BROAD ST
		STREET 2:		STE 1105
		CITY:			CHATTANOOGA
		STATE:			TN
		ZIP:			37402

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XBiotech Inc.
		CENTRAL INDEX KEY:			0001626878
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		8201 E. RIVERSIDE DRIVE
		STREET 2:		BUILDING 4, SUITE 100
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78744
		BUSINESS PHONE:		512-386-2930

	MAIL ADDRESS:	
		STREET 1:		8201 E. RIVERSIDE DRIVE
		STREET 2:		BUILDING 4, SUITE 100
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78744
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2018-10-04</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001626878</issuerCik>
        <issuerName>XBiotech Inc.</issuerName>
        <issuerTradingSymbol>XBIT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001211462</rptOwnerCik>
            <rptOwnerName>MCKENZIE W  THORPE</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>8201 EAST RIVERSIDE DRIVE</rptOwnerStreet1>
            <rptOwnerStreet2>BUILDING 4, SUITE 100</rptOwnerStreet2>
            <rptOwnerCity>AUSTIN</rptOwnerCity>
            <rptOwnerState>TX</rptOwnerState>
            <rptOwnerZipCode>78744</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2018-10-04</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>385000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>3.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>3398600</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>11500</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>Trust</value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>100000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>Foundation</value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes></footnotes>

    <remarks>Effective June 29, 2018, W. Thorpe McKenzie (the &quot;Reporting Person&quot;), a Director of XBiotech, Inc. (the &quot;Company&quot;), adopted a stock trading plan (the &quot;10b5-1 Plan&quot;). For personal tax and financial planning purposes, Mr. McKenzie presently intends to sell up to approximately 15% of his total holdings in the Company in monthly installments, beginning on July 30, 2018 and which will terminate on or before February 28, 2019. The 10b5-1 Plan was adopted in accordance with guidelines specified by Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and the Company's insider trading policies.

Rule 10b5-1 permits corporate officers, directors and others to adopt written, pre-arranged stock trading plans when they are not in possession of material, non-public information. Using these plans, insiders may gradually diversify their investment portfolios and spread stock trades over a period of time regardless of any material, non-public information they may receive after adopting their plans. In accordance with Rule 10b5-1, Mr. McKenzie will have no discretion over the sales of his shares of common stock under the plan. As reflected in this Form 4, W. Thorpe McKenzie (the &quot;Reporting Person&quot;) sold 385,000 shares of XBiotech Inc. common stock in a private transaction on October 4, 2018. The Reporting Person has terminated the 10B5-1 Plan that was put into effect on June 29, 2018.</remarks>

    <ownerSignature>
        <signatureName>/s/ Queena Han under Power of Attorney for W. Thorpe McKenzie</signatureName>
        <signatureDate>2018-10-04</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
